Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Ginkgo Bioworks Holdings (DNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: DNA (3-star) is a REGULAR-BUY. BUY since 13 days. Simulated Profits (-9.68%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 3 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.95% | Avg. Invested days 30 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 784.40M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 6 | Beta 1.55 | 52 Weeks Range 5.00 - 17.58 | Updated Date 10/19/2025 |
52 Weeks Range 5.00 - 17.58 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -136.56% | Operating Margin (TTM) -124.72% |
Management Effectiveness
Return on Assets (TTM) -12.9% | Return on Equity (TTM) -43.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 900556055 | Price to Sales(TTM) 3.4 |
Enterprise Value 900556055 | Price to Sales(TTM) 3.4 | ||
Enterprise Value to Revenue 3.9 | Enterprise Value to EBITDA -1.79 | Shares Outstanding 47089598 | Shares Floating 38690763 |
Shares Outstanding 47089598 | Shares Floating 38690763 | ||
Percent Insiders 3.57 | Percent Institutions 79.28 |
Upturn AI SWOT
Ginkgo Bioworks Holdings
Company Overview
History and Background
Ginkgo Bioworks Holdings, Inc. was founded in 2008 by MIT graduates. It went public in 2021 via a SPAC merger. Ginkgo has evolved from a research lab into a platform company for cell programming.
Core Business Areas
- Cell Programming Platform: Ginkgo designs and engineers organisms for various industries, providing a platform for biological engineering. They leverage automation and data analysis to accelerate the process.
- Biosecurity: Ginkgo is involved in large-scale biosecurity programs, including pathogen monitoring and identification through Concentric by Ginkgo.
Leadership and Structure
Ginkgo Bioworks is led by CEO Jason Kelly. The company has a board of directors with expertise in biotechnology and finance. They have a matrix organization, with teams focused on specific industries and technology platforms.
Top Products and Market Share
Key Offerings
- Cell Programming Services: Ginkgo's core offering is its cell programming platform, used by customers to develop new products and improve existing processes in various industries. Market share in the synthetic biology space is still evolving and difficult to precisely quantify. Competitors include Amyris, Zymergen (acquired by Ginkgo), and Twist Bioscience.
- Concentric by Ginkgo: Concentric is Ginkgo's biosecurity and public health initiative, focusing on pathogen monitoring and outbreak detection. Revenue is project-based with government and public institutions. Competitors in pathogen monitoring include companies like Illumina and Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The synthetic biology industry is experiencing rapid growth, driven by advancements in DNA sequencing, synthesis, and editing technologies. It's seeing investments and expanded applications.
Positioning
Ginkgo is a leading player in the synthetic biology market, with a focus on building a platform for cell programming. Its competitive advantages include its automated foundry, its extensive biological data library, and its diverse customer base.
Total Addressable Market (TAM)
The estimated TAM for synthetic biology ranges from hundreds of billions to trillions of dollars, depending on the applications considered. Ginkgo is positioned to capture a significant share by providing a scalable platform for cell programming.
Upturn SWOT Analysis
Strengths
- Automated Foundry
- Extensive Biological Data Library
- Diverse Customer Base
- Strong Partnerships
- Technological Leadership
Weaknesses
- High Operating Expenses
- Reliance on Customer Projects
- Long Development Cycles
- Negative Profitability
- Complex Business Model
Opportunities
- Expansion into New Industries
- Development of New Platform Capabilities
- Increased Adoption of Synthetic Biology
- Government Funding for Biosecurity
- Strategic Acquisitions
Threats
- Competition from Other Synthetic Biology Companies
- Regulatory Hurdles
- Ethical Concerns
- Economic Downturn
- Technological Disruption
Competitors and Market Share
Key Competitors
- AMRS
- DNA
- CDXS
Competitive Landscape
Ginkgo's advantages include its automated foundry and biological data library. Disadvantages include high operating expenses and reliance on customer projects. It is in a capital intensive industry. Ginkgo Bioworks is positioned to capture a larger market share if it can drive innovation in the space.
Major Acquisitions
Zymergen
- Year: 2022
- Acquisition Price (USD millions): 300
- Strategic Rationale: Acquisition of Zymergen to expand Ginkgo's platform capabilities and access to new technologies and customers.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increasing adoption of the platform and expansion into new markets. (Need to source from reliable sources.)
Future Projections: Analyst projections suggest continued revenue growth driven by platform adoption and new biosecurity initiatives. (Need to source from reliable sources.)
Recent Initiatives: Recent initiatives include acquisitions (Zymergen), partnerships with major corporations, and expansion of the Concentric biosecurity program.
Summary
Ginkgo Bioworks is a leading synthetic biology platform company with a strong technological foundation and diverse customer base. Its high operating expenses and negative profitability are concerns, but its growth opportunities and strategic acquisitions position it for future success. It should look out for competition from others in the same industry and drive costs down as it grows. The recent acquisitions of Zymergen will allow them to expand the services and customer base.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market data is subject to change. Forward looking statements depend on market conditions and Ginkgo Bioworks management team and strategy. All financial figures may be estimates and should be confirmed with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ginkgo Bioworks Holdings
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-19 | Founder, CEO & Director Dr. Jason Kelly Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 834 | Website https://www.ginkgo.bio |
Full time employees 834 | Website https://www.ginkgo.bio | ||
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.